Gut microbiota dysbiosis is associated with altered tryptophan metabolism and dysregulated inflammatory response in COVID-19.
Morgan EssexBelén Millet Pascual-LeoneUlrike LoeberMathias KuhringBowen ZhangUlrike BrüningRaphaela Fritsche-GuentherMarta KrzanowskiFacundo Fiocca VernengoSophia BrumhardIvo RöwekampAgata Anna BieleckaTill Robin LeskerEmanuel WylerMarkus LandthalerAndrej ManteiChristian MeiselSandra CaesarCharlotte ThibeaultVictor Max CormanLajos MarkoNorbert SuttorpTill StrowigFlorian KurthLeif-Erik SanderYang LiJennifer A KirwanSofia Kirke Forslund-StartcevaBastian OpitzPublished in: NPJ biofilms and microbiomes (2024)
The clinical course of COVID-19 is variable and often unpredictable. To test the hypothesis that disease progression and inflammatory responses associate with alterations in the microbiome and metabolome, we analyzed metagenome, metabolome, cytokine, and transcriptome profiles of repeated samples from hospitalized COVID-19 patients and uninfected controls, and leveraged clinical information and post-hoc confounder analysis. Severe COVID-19 was associated with a depletion of beneficial intestinal microbes, whereas oropharyngeal microbiota disturbance was mainly linked to antibiotic use. COVID-19 severity was also associated with enhanced plasma concentrations of kynurenine and reduced levels of several other tryptophan metabolites, lysophosphatidylcholines, and secondary bile acids. Moreover, reduced concentrations of various tryptophan metabolites were associated with depletion of Faecalibacterium, and tryptophan decrease and kynurenine increase were linked to enhanced production of inflammatory cytokines. Collectively, our study identifies correlated microbiome and metabolome alterations as a potential contributor to inflammatory dysregulation in severe COVID-19.